- Home
- SOC vs TOVX Comparison
SOC vs TOVX Comparison
Compare SOC & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOC | TOVX |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 10.1M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | SOC | TOVX |
|---|---|---|
| Price | $4.79 | $0.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $17.33 | $1.00 |
| AVG Volume (30 Days) | ★ 8.1M | 444.6K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.61 | ★ 89.07 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $73.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.88 | $0.16 |
| 52 Week High | $24.96 | $0.86 |
Technical Indicators
Market Signals| Indicator | SOC | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 42.01 |
| Support Level | $4.10 | $0.22 |
| Resistance Level | $5.38 | $0.26 |
| Average True Range (ATR) | 0.32 | 0.01 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 55.56 | 20.90 |
Price Performance
Historical ComparisonAbout SOC Sable Offshore Corp.
Sable Offshore Corp is a Houston-based independent upstream company focused on developing the Santa Ynez Unit in federal waters offshore California. The company operates as one reportable oil and gas segment and is engaged in the acquisition, development, exploration, and production of oil and natural gas.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.